@article{Tsironis2018-vn,

title = {Patterns of practice and pharmacoeconomic analysis of the  management of patients with metastatic renal cell carcinoma  (mRCC) in Greece--the CRISIS study. A retrospective analysis  by the Hellenic Genitourinary Cancer Group (HGUCG)},

author = {Georgiops Tsironis and Konstantinos Koutsoukos and Kostas Athanasakis and Anna Tsiara and Kimon Tzannis and Margarita Gerolympou and Anastasios Visvikis and Georgios Oikonomopoulos and Alexandra Kollia and Efstathia Giannopoulou and Marialena Dimitra and Efthymios Kostouros and Athanasios Papatsoris and Athanasios Dellis and Konstantinos Stravodimos and Ioannis Varkarakis and Epaminontas Samantas and Gerasimos Aravantinos and Nikolaos Kentepozidis and Christos Christodoulou and Vasiliki Bozionelou and Meletios Athanasios Dimopoulos and Aristotle Bamias},

year  = {2018},

date = {2018-11-01},

urldate = {2018-11-01},

journal = {Expert Rev Pharmacoecon Outcomes Res},

volume = {19},

number = {4},

pages = {491--501},

address = {England},

abstract = {Background:Metastatic RCC (mRCC) treatment has been 

 revolutionized with 11 approved targeted agents. We report 

 patterns of practice, outcomes and pharmacoeconomic analyses 

 after the introduction of targeted therapy. Patients and methods: 

 CRISIS was a retrospective multicenter study of mRCCpatients who 

 received targeted therapy . Results were related to the start of 

 1st-line therapy, with a cut off at 1 January 2011 in order to 

 depict the impact of increased availability of effective options. 

 Results: 164 patients, were included. 70.1% and 44.5% received 

 2nd and 3rd-line therapy, respectively. More patients were 

 treated in 2nd-line after 1 January 2011. After a median 

 follow-up of 55.1 months, median progression-free (PFS) and 

 overall survival (OS) were 10.7 (95% confidence intervals [CI]: 

 8.3-13.7), 7.3 (95% CI: 5.1-8.6), 5.8 (95% CI: 3.8-7.8) and 34 

 (95% CI: 28.5-39.8), 22.4 (95% CI: 16-32.1), 18.3 (95% CI: 

 12.4-26.4) months for first, second and third line, respectively. 

 Efficacy of sunitinib and pazopanib in 1st-line were similar. The 

 mean total cost/patient was 35,012.2 Euros (standard deviation 

 [SD]: 28,971.5). Conclusions: Our study confirms previous 

 real-world data suggesting that continuing advances in the 

 treatment of mRCC produce favorable outcomes in everyday 

 practice. Pharmacoeconomic analyses are important for 

 cost-effective utilization of emerging novel therapies.},

keywords = {Greece; Hellenic Genitourinary Cancer Group-HGUCG; metastatic   RCC; pharmacoeconomic analysis; targeted therapy},

pubstate = {published},

tppubtype = {article}

}